LENZ Therapeutics (LENZ) Non Operating Income (2020 - 2026)
LENZ Therapeutics (LENZ) posted quarterly Non Operating Income of $2.6 million for Q1 2026, up 14.49% year-over-year from $2.3 million in Q1 2025, and up 3.04% quarter-over-quarter from $2.6 million in Q4 2025.
LENZ Therapeutics (LENZ) Non Operating Income (2020 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has reported Non Operating Income for 7 consecutive years, with $2.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Income rose 14.49% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $9.8 million (down 15.93% YoY), while the FY2025 annual figure was $9.5 million, up 7.59% from the prior year.
- Non Operating Income improved to $2.6 million in Q1 2026 per LENZ's latest filing, from $2.6 million in the prior quarter.
- Across five years, Non Operating Income topped out at $4.1 million in Q2 2024 and bottomed at -$560000.0 in Q1 2024.
- Historically, Non Operating Income has averaged $1.6 million across 5 years, with a median of $2.2 million in 2022.
- Annual changes were most pronounced in 2022 — Non Operating Income surged 21420.0% — and 2024, when it sank 937.04%.
- LENZ Therapeutics' Non Operating Income stood at $2.2 million in 2022, then tumbled by 48.05% to $1.1 million in 2023, then jumped by 130.23% to $2.6 million in 2024, then fell by 0.19% to $2.6 million in 2025, then advanced by 3.04% to $2.6 million in 2026.
- Business Quant data shows LENZ's Non Operating Income at $2.6 million in Q1 2026, $2.6 million in Q4 2025, and $2.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | LENZ Therapeutics | 147.30 Mn | 147.30 Mn | 5.21 Mn | 2.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.26 Mn |
| Mar 31, 2026 | 2.65 Mn |
| Dec 31, 2025 | 2.57 Mn |
| Sep 30, 2025 | 2.19 Mn |
| Jun 30, 2025 | 2.45 Mn |
| Mar 31, 2025 | 2.31 Mn |
| Dec 31, 2024 | 2.57 Mn |
| Sep 30, 2024 | 2.73 Mn |
| Jun 30, 2024 | 4.10 Mn |
| Mar 31, 2024 | -560,000.00 |
| Dec 31, 2023 | 1.12 Mn |
| Sep 30, 2023 | 985,000.00 |
| Jun 30, 2023 | 233,000.00 |
| Mar 31, 2023 | -54,000.00 |
| Dec 31, 2022 | 2.15 Mn |
| Sep 30, 2022 | 1.47 Mn |
| Jun 30, 2022 | 840,000.00 |
| Mar 31, 2022 | 123,000.00 |
| Dec 31, 2021 | 10,000.00 |
| Sep 30, 2021 | 10,000.00 |